Key facts
- Deep Track Capital, LP filed SCHEDULE 13G for VIRIDIAN THERAPEUTICS, INC. Common Stock, $0.01 par value per share (VRDN).
- Disclosed ownership: 5.3%.
- Date of event: 01 May 2026.
Deep Track Capital, LP - 01 May 2026 SCHEDULE 13G Report for VIRIDIAN THERAPEUTICS, INC. Common Stock, $0.01 par value per share (VRDN)
- Filing Manager
- Deep Track Capital, LP
- Reporting Manager
- Deep Track Capital, LP
- Symbol
- VRDN
- Shares outstanding
- 102,220,000 shares
- Disclosed Ownership
- 5,417,660 shares
- Ownership
- 5.3%
- Form type
- SCHEDULE 13G
- Filing time
- 08 May 2026, 16:17:55 UTC
- Date of event
- 01 May 2026
- Previous filing
- 13 Feb 2026
- SEC
- View on sec.gov
Key filing fact
Deep Track Capital, LP disclosed 5.3% ownership in VIRIDIAN THERAPEUTICS, INC. Common Stock, $0.01 par value per share (VRDN) on 01 May 2026.
Change
- Previous schedule filing date: 13 Feb 2026.
- Current filing was accepted on 08 May 2026, 16:17.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (3)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deep Track Capital, LP | 5.3% | 5,417,660 | 0 | 5,417,660 | /s/ David Kroin | David Kroin, Managing Member of the General Partner of the Investment Adviser | |
| Deep Track Biotechnology Master Fund, Ltd. | 5.3% | 5,417,660 | 0 | 5,417,660 | /s/ David Kroin | David Kroin, Director | |
| David Kroin | 5.3% | 5,417,660 | 0 | 5,417,660 | /s/ David Kroin | David Kroin |
CIK / CUSIP context first